Compare SDEV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDEV | CRDF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 67.1M |
| IPO Year | 2007 | 2012 |
| Metric | SDEV | CRDF |
|---|---|---|
| Price | $0.76 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | ★ 11.4M | 364.0K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $370,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.81 |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.76 | $0.72 |
| 52 Week High | $9.82 | $3.31 |
| Indicator | SDEV | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 30.76 |
| Support Level | N/A | N/A |
| Resistance Level | $1.28 | $1.13 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.01 | 5.60 |
Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.